An AI Firm Wants to Predicts Costly Pharma Flops
Before Biogen Inc.’s experimental Alzheimer’s disease drug failed in a trial last month, analysts surveyed by Bloomberg estimated annual sales of about $3.7 billion by 2023. A German artificial-intelligence firm...
Read More